These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37580307)

  • 1. Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.
    Jiang P; Sun N; Yang W; Xiao L; Zhou L; Gu B; Li Y; Li L; Li J; Li X; Li W; Guo L
    Diabetes Obes Metab; 2023 Nov; 25(11):3356-3365. PubMed ID: 37580307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
    Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
    Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
    Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
    Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
    Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
    Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
    Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
    Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
    Wu Y; Ji T; Lv J; Wang Z
    Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
    Zhao F; Zhou Q; Cong Z; Hang K; Zou X; Zhang C; Chen Y; Dai A; Liang A; Ming Q; Wang M; Chen LN; Xu P; Chang R; Feng W; Xia T; Zhang Y; Wu B; Yang D; Zhao L; Xu HE; Wang MW
    Nat Commun; 2022 Feb; 13(1):1057. PubMed ID: 35217653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
    Knerr PJ; Mowery SA; Douros JD; Premdjee B; Hjøllund KR; He Y; Kruse Hansen AM; Olsen AK; Perez-Tilve D; DiMarchi RD; Finan B
    Mol Metab; 2022 Sep; 63():101533. PubMed ID: 35809773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on peptide-based therapies for type 2 diabetes and obesity.
    Bailey CJ; Flatt PR; Conlon JM
    Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.